Mini Guts Smaller Than A Pea Just Won A $100,000 Startup Prize

"We're literally shipping mini living organs in the mail to people."

That's Charlie Childs, the CEO of a small company in Denver called Intero Biosystems. And he isn't joking.

Intero grows tiny pieces of human intestine in a lab. Each one is about 1 millimeter across, smaller than a grain of rice. The company packs around 100 of them into a tube and sends them to companies that make medicines, food, and chemicals. Those companies use the mini guts to test whether something might hurt a real person's stomach before anyone swallows it.

On October 15, 2026, Intero beat 199 other startups to win Startup Battlefield at TechCrunch Disrupt in San Francisco. The prize: $100,000 and a trophy called the Startup Battlefield Cup. Past companies from the Battlefield program include Trello, Discord, Cloudflare, and Mint.

It's a great story for any kid who likes science. It shows how a lab experiment can turn into a real business.

An organoid is a tiny, simple version of a body organ grown from cells in a lab.

The word sounds fancy, but break it apart: organ plus -oid, which means "like." So an organoid is organ-like.

Here's how Intero makes them, in kid terms:

1. Start with a few regular cells, which can come from a blood sample.
2. Use special chemicals to turn them into "stem cells." Stem cells are like blank cells that can grow into almost any type of cell.
3. Give them the right food and signals so they grow into the different kinds of cells found in an intestine.
4. They clump together into a tiny 3D ball that acts a bit like a real gut.

Intero says its organoids have many tissue types found in a human intestine, not just one flat layer of cells. That's what makes them useful.

[IMAGE: Simple diagram showing a blood cell becoming a stem cell, then a tiny intestine organoid] Alt text: Kid-friendly diagram of how a lab-grown organoid is made from cells Caption: From one cell to a mini gut, in four steps.

To test medicines more safely and learn more about how they affect people.

Before a new medicine reaches a pharmacy, scientists test it many times. For a long time, a lot of that testing happened on animals like mice.

But there's a problem. People aren't mice.

Intero's co-founder Madeline Eiken put it this way: "Most drugs fail clinical trials, and I think it's pretty easy to appreciate that we are neither mice nor flat layers of cells."

A medicine that seems fine in a mouse might still upset a human stomach. A mini human gut could catch some of those problems earlier. That could save time, save money, and reduce how many animals are used in testing.

And the timing is good. In April 2025, the U.S. Food and Drug Administration (FDA), the government agency that approves medicines, announced a plan to reduce its reliance on animal testing and encourage alternatives like organoids.

Intero sells the mini guts, the supplies to use them, and experiments it runs for customers.

This is the business part. Intero has three ways to earn money:

• The product: its mini gut model, called GastroScreen.
• The supplies: the nutrient mixes that feed the cells and the chemicals used in tests. Customers need these to keep the organoids working.
• The service: Intero can design and run experiments for a company, then hand over the results.

That's a smart setup. Think of a video game console. The company sells the console, then sells games and accessories that work with it. Intero sells the mini guts, then sells what you need to use them, plus help.

The company was founded in 2024, spun out of the University of Michigan, and has seven employees. It raised $2.3 million early on and made more than $400,000 in revenue over about a year, from a little under 10 customers.

It means the idea started as research at a school and then became its own company.

Lots of science startups begin this way. A student or professor discovers something in a university lab. They realize people outside the lab would pay for it. So they start a company to make and sell it.

Intero's founders did their early work at the University of Michigan before starting the business. The runner-up at Battlefield, an Australian startup called Apate, also began with university research.

For kids who love science fairs, this is a big idea. Your experiment today could be someone's product tomorrow. You don't have to choose between being a scientist and being a business person.

Young scientists can sketch a "lab to business" plan with a parent on paper, in a notebook, or with Foundra's kids guides, which walk through planning a first business idea.

Yes, and that's normal for any good idea.

Intero isn't the only company making lab-grown gut models. TechCrunch named a few others:

• Altis Biosystems makes intestine models from stem cells.
• InSphero offers gut organoids grown from patient tissue.
• MIMETAS uses "organ-on-a-chip," tiny devices with channels that copy how fluids move through body tissue.

So how does Intero say it's different? Two ways. Its models are more complex, with more tissue types. And because it starts from blood cells instead of tissue from medical procedures, it says it can make more of them more easily.

The company is also honest that it's still proving itself. It's in the second of three testing stages to show its mini guts react the way real human guts do. That's a good lesson: big claims need proof, and good scientists keep testing.

Turn a science topic your kid loves into a pretend business plan in 20 minutes.

Grab paper and answer these together:

1. What science thing do you love? Plants, bugs, weather, rocks, the human body, space.
2. What problem could it help solve? Example: "Plants die when people forget to water them."
3. Who has that problem? Busy parents, teachers with class plants, grandparents.
4. What would you sell? A product, a supply, or a service? Try to think of all three, like Intero.
5. How would you prove it works? What test would you run first?
6. Who else is trying to solve it? Look it up together.

Kids don't need to build anything. If they want to go further, they can share the plan with a teacher or bring it to a science fair as a bonus poster. The goal is to see that science ideas and business ideas can fit together.

Use these at dinner or on the way to school.

• Why might a medicine work in a mouse but not in a person?
• If you could grow a tiny version of any organ, which would you pick? Why?
• Why is it smart for Intero to sell supplies and services, not just the mini guts?
• What does it mean to "prove" something works? How many tests would you want?
• Do you know anyone who works in a lab or a hospital? What could you ask them?

What is Intero Biosystems? It's a Denver startup that grows mini human intestines, called organoids, in a lab. It sells them to drug, food, and chemical companies for testing. It won TechCrunch Startup Battlefield on October 15, 2026.

What is an organoid in simple words? A tiny, simple version of an organ grown from cells in a lab. Intero's are about 1 millimeter across and act a bit like a real human gut.

Will organoids replace animal testing? Not completely yet. They're one of several alternatives the FDA is encouraging. Companies like Intero are still running tests to prove how well their models match real human results.

How much did Intero win at Startup Battlefield? $100,000 and the Startup Battlefield Cup. It beat 199 other startups from the Startup Battlefield 200.

How can my kid explore science businesses? Start with a science fair project, then ask who might pay for the result and why. Visiting a local university science day or museum lab can spark ideas too.

Are organoids safe to handle at home? No. Organoids are grown and used in professional labs with special equipment and safety rules. Kids can learn about them through videos, books, and science programs instead.

1. And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems, TechCrunch, October 15, 2026
2. Intero Biosystems wants drugmakers to test on mini human intestines, not animals, TechCrunch, October 14, 2026
3. GastroScreen platform, Intero Biosystems
4. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs, U.S. Food and Drug Administration, April 2025